Results 31 to 40 of about 24,741 (161)
CLINICAL BLOOD IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS IN KRASNOYARSK REGION
The aim of the study – assessment of the features of clinical blood in patients with juvenile idiopathic arthritis. It showed an increase in the absolute number of lymphocytes and monocytes, platelets, neutrophils, increased erythrocyte sedimentation ...
Julia Semenovna Akopova +2 more
doaj +1 more source
Systemic juvenile idiopathic arthritis is a subtype of juvenile idiopathic arthritis and characterized by arthritis and many systemic features like fever, rash, hepatosplenomegaly, lymphadenopathy and serositis.
Mustafa Çakan +6 more
doaj +1 more source
Treatment of systemic-onset juvenile arthritis with canakinumab
Joachim Peitz, Gerd Horneff Pediatric Rheumatology Centre, Department of General Pediatrics and Neonatology, Asklepios Clinic, Sankt Augustin, Germany Abstract: Treatment of systemic-onset juvenile idiopathic arthritis is challenging, but the ...
Peitz J, Horneff G
doaj
Background Juvenile Idiopathic Arthritis is a term used to describe a wide range of chronic inflammatory diseases, characterized by arthritis of undefined causes persists more than 6 weeks, in children under 16 years old, excluding all other causes of ...
Hanaa El-Banna +6 more
doaj +1 more source
Overview of Juvenile Idiopathic Arthritis
n ...
Malattia, C., Martini, A.
openaire +2 more sources
Juvenile idiopathic arthritis is common rheumatic disease in children and adolescents, but renal involvement is uncommon. Renal involvement is mostly in the form of secondary renal amyloidosis presenting as proteinuria.
Sudeep Patel +5 more
doaj +1 more source
Juvenile idiopathic arthritis is a chronic inflammatory disease of the joints in children, mainly of autoimmune or auto-inflammatory nature. It is a heterogeneous group, which includes different subtypes of the disease. Different mechanisms may play role
I. M. Krivolapova +2 more
doaj +1 more source
CLINICAL CASE OF TOCILIZUMAB USE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
The article presents a case of successful use of a preparation of monoclonal antibodies to interleukin 6 receptors (tocilizumab) at asevere systemic juvenile idiopathic arthritis.
O. L. Lomakina +4 more
doaj +1 more source
Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
Miho Murakami,1 Minako Tomiita,2,3 Norihiro Nishimoto11Laboratory of Immune Regulation, Wakayama Medical University, Wakayama, 2Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, 3Department of Allergy and Rheumatology, Chiba
Murakami M, Tomiita M, Nishimoto N
doaj
Participation in Juvenile Idiopathic Arthritis [PDF]
Juvenile idiopathic arthritis (JIA) can influence all aspects of a child’s life as well as that of the family, and healthcare providers increasingly recognize that improved health-related quality of life (HRQOL), physical activity, and community participation are important treatment goals. Physical activity is essential for optimal physical, emotional,
openaire +2 more sources

